671 results about "Colonic Cancers" patented technology

The invention belongs to the technical field of medicines, and relates to tetrahydropyridopyrimidine compounds as well as a preparation method and application thereof, in particular to tetrahydropyridopyrimidine compounds or pharmaceutically acceptable salts thereof as well as a preparation method and application thereof in preparation of antitumor drugs. The structure of the tetrahydropyridopyrimidine compound or the pharmaceutically acceptable salt thereof is as shown in a general formula (I), and R1-R4 are as shown in the specification and claims. The compound provided by the invention can be used for preparing a KRAS G12C inhibitor, is used for inhibiting G12C mutation of KRAS, has an obvious inhibiting effect on lung cancer, pancreatic cancer or colon cancer, and can be used for preparing antitumor drugs. # imgabs0 #

The invention relates to the technical field of CT (Computed Tomography) image analysis and labeling, in particular to a method for finely labeling colon cancer lesions in CT images. The method comprises the following steps: firstly, acquiring an intestinal wall section corresponding to each non-intestinal wall section area in an intestinal wall section area in a CT image; analyzing and acquiring an abnormal index of each pixel point in each non-intestinal-wall section area; based on the abnormal index and the distribution characteristic of each pixel point, obtaining all focus sub-regions; analyzing and acquiring a focus score of each focus sub-region, and further combining different focus sub-regions to acquire all focus regions; and finally, screening out a to-be-marked focus area from all focus areas and marking the to-be-marked focus area. According to the method, by analyzing the characteristics that the texture of the intestinal wall surface and the shape of the intestinal wall cross section are changed due to colon cancer, and further combining the area characteristics and the distribution characteristics of the lesions in different lesion stages, the lesion region is accurately obtained and marked, and the marking effect of the colon cancer lesion is improved.

The invention relates to an antibody drug conjugate and a preparation method and application thereof. The present invention relates to antibody drug conjugates for use in the treatment of HER3 positive cancers. The invention provides a fully human-derived HER3 antibody which has excellent binding activity to HER3 positive cells and can be used for efficiently delivering a medicine to the HER3 positive cells. The present application also provides a drug-linker molecule for coupling to the antibody, the drug comprising a DNA topoisomerase inhibitor. The prepared antibody drug conjugate has a better drug-antibody coupling ratio, and has a very good targeted killing effect on colon cancer, gastric cancer, breast cancer and lung cancer (such as non-small cell lung cancer, particularly lung adenocarcinoma). Therefore, the invention further provides a preparation method of the antibody drug conjugate and application of the antibody drug conjugate in treatment of HER3 positive cancers.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a series of substituted oxadiazole compounds as well as a preparation method and application thereof. Pharmacological tests show that the series of compounds have strong selectivity and inhibition effect on SphK2, and have anti-proliferation effect on cervical cancer cells, prostate cancer cells and colon cancer cells.

This invention belongs to the field of biomedical technology, specifically disclosing a pharmaceutical composition for treating PIK3CA-mutated colorectal cancer and the application of Alpelisib and Menin-MLL complex inhibitors in combination therapy for colorectal cancer. Experimental results show that the combined use of Alpelisib and Menin-MLL 1 / 2 interaction inhibitors can synergistically inhibit the growth of PIK3CA-mutated colorectal cancer PDX tumors and even induce tumor regression, demonstrating better therapeutic effects than Alpelisib alone. The combination of the two has a synergistic therapeutic effect.

It is an object of the present invention to provide drugs that bind specifically to FAPα, are effective in the treatment and diagnosis of tumors or cancers expressing FAPα, for example, in the treatment and diagnosis of solid cancers such as pancreatic cancer, sarcoma, esophageal cancer, lung cancer, breast cancer, prostate cancer, head and neck cancer, ovarian cancer, colon cancer, neuroendocrine tumor, thyroid cancer, uterine cancer, liver cancer and the like (particularly, pancreatic cancer), and have a lower risk of prolonged side effects. The present invention provides a conjugate comprising a radioactive moiety comprising an aryl group substituted with a radionuclide selected from 211At, 210At, 131I, 125I, 124I, 123I, 77Br and 76Br, and a bioactive moiety having an affinity for fibroblast activation protein α (FAPα).

The invention relates to the field of image analysis, in particular to a colon cancer lymph node metastasis risk prediction method and system based on image analysis. The method comprises the following steps: acquiring a pathological section scanning image, carrying out layer-by-layer downsampling and feature reconstruction, and generating pathological section topological features; carrying out adaptive clustering analysis and multi-parameter fusion evaluation on the basis of the pathological section topological features to obtain independent migration evaluation values of individual tumor cells; performing tumor metastasis branch analysis according to the independent migration evaluation value, and constructing a metastasis branch path distribution diagram; extracting an immunohistochemical staining image of a patient to obtain immune cell space distribution data; and performing multi-region lymphatic metastasis simulation and metastasis risk situation prediction based on the immune cell spatial distribution data and the metastasis branch path distribution diagram to obtain a final metastasis risk assessment result. According to the method, the lymph node metastasis risk is accurately and efficiently analyzed, and the credibility of a pathological analysis result is improved.

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cyclophosphamide ternary nano-micelle and a preparation method thereof.The cyclophosphamide ternary nano-micelle prepared through the method can be used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like. Reasonable preparation steps and a preparation formula are adopted, the use of an organic reagent is reduced, the irritation of cyclophosphamide is reduced and the stability of the micelle is improved by adjusting a freeze-drying technology, and the cyclophosphamide micelle adopts amphiphilic macromolecules as a carrier material, so that the drug loading capacity and the stability of the micelle are obviously improved, and the bioavailability of the micelle is improved. The ternary nano-micelle system has the advantages that the solubility of cyclophosphamide is improved, the in-vivo bioavailability is increased, the preparation method is simple, the micelle performance is stable, and large-scale industrial production is facilitated.

The invention discloses a multi-dimensional efficacy evaluation system for colon cancer targeted drug screening, and relates to the technical field of medical assistance. Comprising a data acquisition module, an inference engine module and an output module. The data acquisition module acquires an organ sample response data set (including apoptosis rate A1, activity decline degree A2 and image structure change score B1) and a patient background data set (including gene mutation discrete variable set G and metabolic pathway continuous variable set M). The inference engine module executes dominant condition rules: generating a negative weight factor alpha according to a gene mutation state and a metabolic activation threshold value; generating a deduction item gamma based on a preset drug-resistant mutation subset; performing weighted calculation on the apoptosis rate and the activity decline degree to generate a basic drug effect score beta, and increasing beta through a critical value; and finally generating a comprehensive response score S. And the output module outputs a drug effect judgment result according to the S, and multi-dimensional accurate evaluation is realized.

An antibody-drug conjugate and a preparation method therefor and a use thereof, in particular, an antibody-drug conjugate for treating HER3-positive cancers. The antibody-drug conjugate contains a fully human HER3 antibody, has excellent binding activity to HER3-positive cells, and can efficiently deliver a drug to HER3-positive cells. The antibody-drug conjugate has a good drug-antibody coupling ratio, and has a good targeted killing effect on colon cancer, gastric cancer, breast cancer, and lung cancer (e.g., non-small cell lung cancer, specifically lung adenocarcinoma). Therefore, further provided are a method for preparing the antibody-drug conjugate and a use of the antibody-drug conjugate in treatment of HER3-positive cancers.

The invention provides a preparation method and application of a turmeric extracellular vesicle targeted drug delivery system with an anti-colon cancer effect. The engineering system of modifying CELNs and loading DOX by the TCP-1 colon cancer targeting peptide is constructed by extracting curcuma longa extracellular vesicles (CELNs). The system of loading adriamycin through targeted modified turmeric extracellular vesicles has better anti-tumor activity and tumor targeting property, and HE staining and serum detection results show that the system has no significant influence on important tissues, visceral organs and liver functions of mice. And the biological safety is improved while a better treatment effect is achieved.

The invention discloses a novel polypeptide, a polypeptide derivative and application thereof, and belongs to the technical field of biological medicine. The invention specifically relates to a specific sequence, a discovery process, a specific anti-tumor type, a long-acting modification mode and application of the novel polypeptide. The tumors comprise one or more of brain glioma, neuroblastoma, head and neck cancer, esophagus cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestinal cancer, ileocecum cancer, stomach cancer, bladder cancer, pancreatic cancer, prostate cancer, bile duct cancer, melanoma, sarcoma, myeloma, lymphoma and leukemia; the compound has the specific effect of inhibiting proliferation and / or metastasis of tumor cells, is wide in treatment spectrum and has important treatment value in various tumors.

The invention discloses application of a target protein circPIAS1-108aa inhibitor combined with oxaliplatin in preparation of a medicine synergistic composition for treating cancers, the specific action mechanism of circPIAS1-108aa in colon cancer treatment is found for the first time, and further research shows that by using siRNA to knock down circPIAS1-108aa, colon cancer cell proliferation can be remarkably inhibited, and the effect of treating the colon cancer can be achieved. Furthermore, the target spot protein circPIAS1-108aa inhibitor can be used for enhancing the treatment effect of the oxaliplatin. Therefore, when the circPIAS1-108aa expression is inhibited in a targeted manner and the oxaliplatin is combined for use, the circPIAS1-108aa can be obviously used for preventing and treating cancers, the dosage and toxic and side effects of the oxaliplatin are reduced, and a new synergistic strategy is provided for tumor treatment.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 3-sulfamoyl benzamide compound as well as a preparation method and application thereof. The 3-sulfamoyl benzamide compound has a structure as shown in a formula I. In the formula I, X is chlorine or trifluoromethyl; r1 and R2 are independently C1-4 alkyl or R1, R2 and N atoms connected with R1 and R2 jointly form a heterocyclic group, and the heterocyclic group is a substituted or unsubstituted five-membered or six-membered heterocyclic group; and when the heterocyclic group is a substituted heterocyclic group, the substituent group in the substituted heterocyclic group is one or more of C1-4 alkyl, phenyl and acetyl. The 3-sulfamoyl benzamide compound disclosed by the invention has a remarkable proliferation inhibition effect on HCT116 colon cancer cells, HeLa human cervical cancer cells, MDA-MB-231 human breast cancer cells and A375 human malignant melanoma cells.

The invention belongs to the field of medical image processing and artificial intelligence, and provides a colon cancer CT image segmentation method and system fusing individualized features, and the method comprises the steps: obtaining the abdomen CT images of a historical patient and a target patient; obtaining structured individual feature information related to the patient, wherein the individual feature information comprises age, gender, colon cancer family history and intestinal medical history information; preprocessing the abdomen CT image; and training an image segmentation model by using the preprocessed abdominal CT image of the historical patient, segmenting the preprocessed abdominal CT image of the target patient by using the trained image segmentation model meeting the segmentation precision requirement, and generating a colon cancer focus segmentation image conforming to the individual feature difference of the target patient. According to the method, the structured patient information is utilized to guide the model network to adjust the feature response, so that the segmentation precision and individual adaptability of the model are improved, and the segmentation accuracy is further improved.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The present invention relates to a method for constructing a gene network through a single-cell transcriptome and a method for discovering key genes in differentiation using same, and a composition for the prevention, alleviation, or treatment of colon cancer using the target discovered through the method. The method for constructing a gene network of key genes according to the present invention employs single-cell transcriptome data and thus can be applied to all single-cell transcriptome data. The combination of MYB / HDAC2 / FOXA2 discovered upon application to colon cells can serve as a cancer treatment target that promotes the differentiation of colon cancer cells to revert same into differentiated normal cells.

The invention discloses a Pol theta inhibitor as well as a preparation method, a pharmaceutical composition and application thereof. The compound disclosed by the invention is shown as a general formula (I), further comprises stereoisomers, pharmaceutically acceptable salts or a mixture of the stereoisomers and the pharmaceutically acceptable salts, can effectively inhibit Pol theta enzyme activity, is used for preparing medicines for treating colon cancer and breast cancer, and is wide in application, the preparation method is high in applicability, and the structure is easy to expand. # imgabs0 #

The invention discloses a podophyllotoxin triazole ether derivative as well as a preparation method and application thereof, belongs to the technical field of chemical pharmacy, and particularly relates to a podophyllotoxin triazole derivative and application of the podophyllotoxin triazole ether derivative in preparation of antitumor drugs. A series of novel 1, 2, 3-triazole podophyllotoxin derivatives are designed and synthesized by combining a triazole structure with a podophyllotoxin matrix through click chemistry reaction, the dynamic characteristics of podophyllotoxin are optimized by introducing the triazole structure, and the anti-cancer effect and druggability of podophyllotoxin are improved. Molecular docking shows that the series of compounds have relatively strong binding energy to AKT1 and tubulin and can inhibit tubulin / AKT1 in a targeted manner, and in-vitro anti-tumor activity research shows that the molecules have very strong inhibitory activity to proliferation of human colon cancer cell strains, and a new strategy can be provided for structural derivatization of podophyllotoxin. # imgabs0 #

The present invention relates to a bioactive composition, with an antitumor effect, obtained from the transformation by alkylation and esterification reaction of an extract of the «Stipa tenacissima L» esparto plant. Said composition comprises at least one lupeol and / or β-sitosterol derivative selected from formulae (III) to (VI) obtained by alkylation or esterification reaction with a very high cytotoxicity efficiency.

The invention belongs to the technical field of biological medicine, and particularly relates to application of astaxanthin vesicles in preventing and relieving colon cancer, and the astaxanthin vesicles have at least one of the following applications: oxidation resistance; anti-inflammation; the antibacterial effect is achieved; the phagocytic ability of macrophages is promoted; the intestinal health is improved; tumor cell proliferation is resisted; preventing and / or treating tumors; the preparation method of the embedding body comprises the following steps: S1, mixing an iRGD peptide ligand, a hyaluronic acid ligand and a solution containing vesicles to obtain a carrier; s2, enabling the carrier to be in contact with astaxanthin, so as to obtain the embedding body. According to the application, the astaxanthin is embedded into the targeting carrier, so that the astaxanthin is effectively protected from being influenced by an in-vivo environment, and meanwhile, the astaxanthin is accurately targeted to target parts such as macrophages in a tumor microenvironment, so that the concentration of a medicine at a diseased region is improved, the side effect on normal tissues is reduced, and the curative effect of the medicine is improved. The astaxanthin can safely and efficiently reach a target site and exert multiple functions of oxidation, anti-inflammation, antibiosis and the like.

The invention discloses an aza-four-membered ring connected pyrazolopyridine compound or pharmaceutically acceptable salt and application thereof, and the compound with the structure can be used as a novel high-selectivity PDE10A inhibitor for treating peripheral tissue diseases such as cardiac hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal function impairment and renal fibrosis. Lung inflammation and pulmonary fibrosis, immune regulation disorder and cancers (colon cancer, ovarian cancer and lung cancer). Through strategies in two aspects, the inhibition effect of the compound on a PDE10A high-selectivity inhibitor is reduced while the inhibition effect of the compound on a central nervous system is reduced. Firstly, in the aspect of molecular structure modification, the structure of the pyrazolopyridine compound connected with the aza-four-membered ring is optimized, for example, the polar surface area of molecules is increased by increasing the proportion of the number of N, O and S atoms in the molecular structure, and the fat solubility is reduced; and hydrophilic groups are introduced to increase water solubility and the like, so that the permeability of the compound to the blood brain barrier BBB is reduced. And 2, targeted drug delivery of lung tissues is realized by means of a pharmaceutical preparation.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The invention is applicable to the technical field of biological medicines, provides application of a natural compound of a targeted colon cancer drug resistance related protein, and particularly relates to application in preparation of drugs for preventing or treating colon cancer. According to the invention, a natural small molecule compound neohesperidin dihydrochalcone targeting the colon cancer drug resistance related protein TAGLN is screened out, and a new scheme is provided for reversing colon cancer drug resistance, so that the situation that no drug is available to the target spot is solved. Secondly, the invention also provides a scheme for combined use of neohesperidin dihydrochalcone and oxaliplatin, the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, and a new choice is provided for clinical treatment of colon cancer.

The invention discloses a strain of Lactobacillus paracasei DACN623 and an application of the Lactobacillus paracasei DACN623 in prevention and treatment of colon cancer, and particularly discloses a strain of Lactobacillus paracasei DACN623 and a preparation method of the Lactobacillus paracasei DACN623. The Lactobacillus paracasei DACN623 separated from Inner Mongolian mare's milk has the characteristics of acid resistance and bile salt resistance, a strain hemolytic evaluation experiment shows that the Lactobacillus paracasei DACN623 has safety, and the experiment proves that the Lactobacillus paracasei DACN623 has good anti-colon cancer activity; furthermore, in-vivo experiments show that the relieving effect of the compound on colon cancer mice is achieved, and it is proved that the compound has the excellent colon cancer resisting effect. The lactobacillus paracasei DACN623 provided by the invention can obviously inhibit cell proliferation, can be developed into an anti-tumor probiotic preparation, and has a good application prospect.

In some embodiments, the present disclosure relates to a method. The method includes extracting a plurality of pre-treatment features from one or more first regions of interest (ROI) within pre-treatment imaging data. Prognostic pre-treatment features are identified from the plurality of pre-treatment features. The prognostic pre-treatment features are determinative of a treatment response. A plurality of post-treatment features are extracted from one or more second ROI within post-treatment imaging data. Prognostic post-treatment features are extracted from the plurality of post-treatment features. The prognostic post-treatment features are determinative of the treatment response. Prognostic tumor diversity features are determined from a common subset of the prognostic pre-treatment features and the prognostic post-treatment features. A machine learning stage is operated to generate a medical prediction of the treatment response for a bowel cancer patient using the prognostic tumor diversity features.

The invention discloses an application of a training immune agonist in preparation of a drug for sensitizing radiotherapy treatment of tumors, and researches show that the training immune agonist significantly activates immune response of a body by promoting expression of inflammatory cytokines, enhancing phagocytic ability of macrophages, recruiting immune cells and amplifying an immune activation effect, so that the immune response of the body is enhanced. The sensitivity of tumor cells to radiotherapy is improved, and a dual mechanism of'radiotherapy sensitization-immune synergy 'is formed, so that the bottleneck of the traditional radiotherapy curative effect is broken through, the local control rate of radiotherapy is improved, and the recurrence risk is reduced. Experiments prove that the training immune agonist combined with radiotherapy has a remarkable treatment effect on various highly invasive tumors (such as brain glioma and lung cancer brain metastasis) and common malignant tumors (such as colon cancer and lung cancer), and shows wide applicability. The invention provides a new combined therapy direction for tumor treatment, is expected to improve the prognosis of patients, prolong the lifetime and improve the life quality, and has important clinical transformation value.

The invention belongs to the technical field of cancer drugs, and particularly relates to a pancreatin-responsive bioactive peptide, nanofiber hydrogel prepared from the pancreatin-responsive bioactive peptide and application of the pancreatin-responsive bioactive peptide. The trypsin response-based bioactive peptide 1-Pept (the sequence of the trypsin response-based bioactive peptide 1-Pept is naphthylacetic acid-phenylalanine-glycine-tyrosine-lysine-cysteine-aspartic acid) and an anti-cancer drug adriamycin can be jointly assembled into 1-Pept / Dox nanofiber hydrogel, and a cytoskeleton can be destroyed by combining nanofibers with Dox; a series of cascade events resulting in cellular dysfunction are initiated, including mitochondrial damage, activation of apoptosis-associated proteins, and nuclear damage, thereby cooperatively causing tumor ablation. Compared with the existing single anti-cancer drug adriamycin, the in-vivo and in-vitro anti-cancer effect of the compound is obviously superior to that of the adriamycin pure drug, and the compound has obvious advantages in the aspect of resisting colon cancer.

The invention discloses application of combination of okannin and epirubicin in prevention and / or treatment of colon cancer, relates to the technical field of biological medicine, and is technically characterized in that a pharmaceutical composition comprises okannin and epirubicin, the preferable molar ratio is 15: 1 or 7.5: 1, and the pharmaceutical composition aims to reduce the dosage of epirubicin, reduce toxic and side effects and enhance the curative effect through a synergistic effect. The invention also comprises a method for detecting the influence of the pharmaceutical composition on colon cancer cell viability and apoptosis, and an animal model for evaluating the influence on the tumor growth of a colon cancer tumor-bearing mouse. The pharmaceutical composition disclosed by the invention can be used for remarkably inhibiting the proliferation of colon cancer cells and enhancing the apoptosis promoting effect of epirubicin, and shows a good anti-tumor effect and relatively low visceral organ toxicity in an animal model. The invention provides a safe and effective new treatment strategy for colon cancer patients.